細胞番号 : 細胞名
RCB0526 : Jyg-MC(A)
update : 2022/12/21
|
| 細胞特性(Comment:英) | murine mammary tumor cell lines. High level MMTV producer line. |
| 細胞特性(日) | 多量のMMTVを産生するマウス乳癌。MLVも含んでいる。ヌードマウスへ の移植６週後でほぼ100%肺に転移する。 |
| 細胞特性(寄託者記述:英) | |
| 細胞特性(寄託者記述:日) | |
| 使用条件(英) | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| 使用条件(日) | 基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。 |
| 備考(英) | |
| 備考(日) | |
| 提供申込書類(英) |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
| 提供申込書類(日) |
依頼書C-0001.pdf
同意書(非営利学術目的)C-0003.pdf
同意書(営利目的)C-0003p.pdf
|
|
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
|
| 提供手数料 |
手数料とお支払いについてはこちらをご覧ください。 |
|
細胞基本情報
|
|
寄託者 |
Morimoto, Junji
|
| 樹立者 |
Morimoto, Junji
|
| 寄託日 |
1990
|
| 動物種 |
_mouse
< Mammals
|
| 動物系統名 |
JYG
|
| 性別 |
Female
|
| 採取組織 |
mammary
|
| 病名 |
mammary tumor
|
| 転移 |
Yes
|
| 転移巣 |
lung, liver,spleen
|
| 細胞分類 |
cancer
|
| 初代培養日 |
1987
|
|
細胞寿命 |
infinite
|
| 細胞形態 |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_H216
|
|
細胞培養・検査情報
| |
寄託時情報 |
ロット情報 |
| 培地・試薬情報 |
培地・試薬一覧はこちらをご覧ください。 |
|
培養形態 |
|
Adherent cells
|
| 培地 |
|
DMEM (low glucose) + 10% FBS
|
| 抗生物質 |
|
Free
|
|
継代方法 |
|
0.25% Trypsin
|
|
継代密度 |
|
1 : 8 split
|
| 継代・培地交換頻度 |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
| 培養最適温度 |
|
37
℃
|
| 二酸化炭素濃度 |
|
5
%
|
| 凍結培地 |
|
Medium + 10% DMSO
|
| 凍結方法 |
|
Slow freezing
|
| マイコプラズマ |
|
(-)
|
| マウス系統検査 |
|
OK
|
| アイソザイム検査 |
|
LD, NP, G6PD
|
| 染色体検査 |
|
38-126(50) : /39(7),40(11),41(4),55(1),58(2),59(1)/
|
| 画像情報 |
寄託時情報 | ロット情報 |
|
|
|
| 文献情報 |
Reference(英) |
9件
|
| Reference(日) |
0件
|
| 利用者成果(英) |
8件
|
| 利用者成果(日) |
0件
|
| Reference(英) |
|
979
Shibata MA, Ambati J, Shibata E, Albuquerque RJ, Morimoto J, Ito Y, Otsuki Y.
The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model
BMC Med
2010
8:69
PubMed ID: 21047425
|
|
986
Shibata MA, Shibata E, Morimoto J, Eid NA, Tanaka Y, Watanabe M, Otsuki Y.
An immunocompetent murine model of metastatic mammary cancer accessible to bioluminescence imaging
Anticancer Res
2009
29(11):4389-95
PubMed ID: 20032383
|
|
978
Shibata MA, Morimoto J, Shibata E, Otsuki Y.
Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model
Cancer Gene Ther
2008
15(12):776-86
PubMed ID: 18654613
DOI: 10.1038/cgt.2008.43
|
|
974
Shibata MA, Morimoto J, Akamatsu K, Otsuki Y.
Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses
Med Mol Morphol
2008
41(1):34-43
PubMed ID: 18470679
DOI: 10.1007/s00795-007-0388-1
|
|
975
Shibata MA, Morimoto J, Doi H, Morishima S, Naka M, Otsuki Y.
Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis
Cancer Gene Ther
2007
14(3):268-78
PubMed ID: 17096028
DOI: 10.1038/sj.cgt.7701009
|
|
1004
Shibata MA, Morimoto J, Ito Y, Kusakabe K, Otsuki Y.
Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer
Med Electron Microsc
2004
37(4):216-24
PubMed ID: 15614446
DOI: 10.1007/s00795-004-0247-2
|
|
1001
Shibata MA, Morimoto J, Otsuki Y.
Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation
Cancer Gene Ther
2002
9(1):16-27
PubMed ID: 11916241
DOI: 10.1038/sj.cgt.7700415
|
|
1432
Morimoto J, Imai S, Haga S, Iwai Y, Iwai M, Hiroishi S, Miyashita N, Moriwaki K, Hosick, H L
New murine mammary tumor cell lines.
In Vitro Cell Dev Biol
1991
27A:349-51
PubMed ID: 2071538
DOI: 10.1007/BF02630952
|
|
1003
Kiyozuka Y, Asai A, Senzaki H, Uemura Y, Nakashima A, Morimoto J, Matsuzawa A, Tsubura A.
Telomere length, telomerase activity and telomerase RNA expression during mouse mammary tumor progression
Int J Mol Med
1988
2(4):437-44
PubMed ID: 9857231
DOI: 10.3892/ijmm.2.4.437
|
| 利用者成果(英) |
|
12491
Seo I, Cho JH, Lee MH, Park WJ, Kwon SY, Lee JH.
Clinical and Prognostic Value of Human Mammary Tumor Virus in Korean Patients with Breast Carcinoma
Ann Clin Lab Sci
2019
49(2):171-174
PubMed ID: 31028060
|
|
10266
San TH, Fujisawa M, Fushimi S, Yoshimura T, Ohara T, Soe L, Min NW, Kyaw O, Yang X, Matsukawa A.
Low prevalence of human mammary tumor virus (HMTV) in breast cancer patients from Myanmar.
Infect. Agents Cancer
2017
12:20
PubMed ID: 28413435
DOI: 10.1186/s13027-017-0130-0
|
|
14650
akano N, Tsuchiya Y, Kako K, Umezaki K, Sano K, Ikeno S, Otsuka E, Shigeta M, Nakagawa A, Sakata N, Itoh F, Nakano Y, Iemura SI, van Dinther M, Natsume T, Ten Dijke P, Itoh S.
TMED10 Protein Interferes with Transforming Growth Factor (TGF)-β Signaling by Disrupting TGF-β Receptor Complex Formation
J Biol Chem
2017
292(10):4099-4112.
PubMed ID: 28115518
DOI: 10.1074/jbc.M116.769109
|
|
14659
Okita Y, Kimura M, Xie R, Chen C, Shen LT, Kojima Y, Suzuki H, Muratani M, Saitoh M, Semba K, Heldin CH, Kato M.
The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Sci Signal
2017
10(474):eaak9397
PubMed ID: 28400538
DOI: 10.1126/scisignal.aak9397
|
|
7147
Hiraga T, Ito S, Nakamura H.
EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation.
Int. J. Cancer
2016
138:1698-708
PubMed ID: 26576938
DOI: 10.1002/ijc.29921
|
|
8619
Lee TL, Li Y, Alba D, Vong QP, Wu SM, Baxendale V, Rennert OM, Lau YF, Chan WY.
Developmental staging of male murine embryonic gonad by SAGE analysis.
J Genet Genomics
2009
36:215-27
PubMed ID: 19376482
DOI: 10.1016/S1673-8527(08)60109-5
|
|
3952
Akatsu T, Ono K, Katayama Y, Tamura T, Nishikawa M, Kugai N, Yamamoto M, Nagata N.
The mouse mammary tumor cell line, MMT060562, produces prostaglandin E2 and leukemia inhibitory factor and supports osteoclast formation in vitro via a stromal cell-dependent pathway.
J Bone Miner Res
1998
13(3):400-8
PubMed ID: 9525340
DOI: 10.1359/jbmr.1998.13.3.400
|
|
18041
Ding Y, Tan W, Hu R, Chen W, Hou Y.
Construction of a novel fusion protein harboring mouse interferon gamma and epidermal growth factor receptor binding domain and enhancement of its antitumor activity
Sci China C Life Sci
1997
40(3):293-300
PubMed ID: 18726330
DOI: 10.1007/BF02879090
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト